Sequenced at Birth

An NIH program will study the promises and pitfalls of sequencing newborns’ genomes.

By | September 5, 2013


The National Institutes of Health (NIH) announced a $25 million project yesterday (September 4) aimed at ensuring researchers, clinicians, and families are ready for a future in which genome sequencing is more affordable and available from birth. Research teams at four sites will embark on five-year studies to explore exactly how babies’ genome sequences might be used in their health care—as well as the ethical and legal ramifications of such knowledge.

There are already several standard tests to screen for genetic disorders in newborns. Rather than replace these, genome sequencing could provide additional information for preventative medical care.

Alan Guttmacher, director of the National Institute of Child Health and Human Development, told reporters that sequencing could “become part of the electric health record that could be used throughout the rest of the child’s life both to think about better prevention but also to be more alert to early clinical manifestations of a disease,” according to Science.

But the data come with concerns. More screening could mean more false positives, which, as Nature mentioned, “can have profound effects on families even if a child never becomes sick.”

Often it’s doctors who decide how much genomic information parents should know. One of the NIH-backed projects, centered at Brigham and Women’s Hospital in Boston, will explore this question by sequencing hundreds of infants’ genomes and tracking how the resulting knowledge impacts the children and their parents over time. 

At Children’s Mercy Hospital in Kansas City, Mo., another team will investigate the benefits genome sequencing might offer to newborns in neonatal intensive care units, where quick diagnoses can be critical. Finally, researchers at the University of North Carolina at Chapel Hill and University of California, San Francisco, will look into the possibility of using partial genome sequencing to enhance existing newborn screening tests.

“I think we’re five to 10 years away from the time when it will be very easy and very inexpensive for any parent who wants genomic sequencing of their newborn to obtain it,” Robert Green of Brigham and Women’s Hospital told WBUR. “And it may be even sooner than that.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: geneyouin


Posts: 6

September 6, 2013


It is ironic that this analysis of inherited genetic diseases is performed after birth, when the disease prevention window is already closed.   This is yet another example of “reactive” Western Medicine approach which aimed at treating the symptoms rather than the cause of disease. These funds will be better spent on population screening of prospoecive parents for prevention of genetic diseases? 

Replied to a comment from geneyouin made on September 6, 2013

September 8, 2013

Sadly with a lot of western medicine one makes far more profits by treating symptoms then by curing or preventing a disease, and American medicine is extremely profit oriented.

Screening before potential conception also raises a complicated issue for the potential parents of  "should we procreate" when they are told their child will have a high (or near certain) probility of being born with one (or more) genetic diseases.

Ultimately for most married couples I suspect the desire to sire offspring will out weight any such evidence that their child be have genetic disease x, y, z (or whatever.)

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Immune Checkpoint Found Lacking in Type 1 Diabetes
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.